Exio Biosciences is addressing the clinical need to develop an advanced blood-based diagnostic test to predict a patient’s responsiveness to cancer immunotherapy drugs.

Innovating immuno-oncology diagnostics – helping cancer patients

PD-1/PD-L1 immunotherapies are disruptive drugs that are changing how we treat cancer.

Unfortunately, not all patients provide a durable response to these therapeutics and often suffer severe side effects

Exio’s liquid biopsy offering will help guide physician decisions on which cancer patients have the highest likelihood of long-term cure using checkpoint inhibitors that target PD-1/PD-L1.

Exio has created a specific and sensitive test that evaluates exosomes in the blood to address this problem and transform immuno-oncology.

Innovating immuno-oncology diagnostics – helping cancer patients

Exio has created a specific and sensitive test that evaluates exosomes in the blood to address this problem and transform immuno-oncology.

PD-1/PD-L1 immunotherapies are disruptive drugs that are changing how we treat cancer.

Unfortunately, not all patients provide a durable response to these therapeutics and often suffer severe side effects

Exio’s liquid biopsy offering will help guide physician decisions on which cancer patients have the highest likelihood of long-term cure using checkpoint inhibitors that target PD-1/PD-L1.